Clinical Study Of Omalizumab In The Treatment Of Allergic Asthma

Objectives:To investigate the clinical efficacy of Omalizumab in the treatment of moderate to severe allergic asthma.Methods:The subjects were 32 patients with moderate to severe allergic asthma who were treated with Omalizumab for ≥ 16 weeks from 2021.07 to 2022.12 in the First Hospital of Jilin University,and their clinical characteristics were analyzed.The changes of asthma control test(ACT)score,peripheral blood eosinophil count(Eo S),serum total Ig E,exhaled nitric oxide(Fe NO),forced expiratory volume in one second(FEV1),percentage of forced expiratory volume in one second to predicted value(FEV1 % pred)and forced expiratory volume in one second / forced expiratory volume(FEV1 / FVC)before and after treatment were compared,and the adverse reactions during treatment were observed.Results:After 16 weeks of Omalizumab treatment,the ACT score increased from(9.21± 2.70)to(20.37 ± 1.99)(P < 0.05).Blood eosinophil count(Eo S)decreased from(321.3 ± 0.046)106 / L to(286.3 ± 0.036)106 / L(P < 0.05).Serum total Ig E increased from(431.56 ± 46.61)IU / ml to(479.56 ± 69.90)IU / ml(P > 0.05).Fe NO50 decreased from(73.25 ± 14.00)ppb to(46.84 ± 9.84)ppb(P < 0.05).Fe NO200 decreased from(38.52 ± 5.30)ppb to(22.62 ± 3.36)ppb(P < 0.05).FEV1 increased from(2.26 ± 0.14)to(2.41 ± 0.13)(P <0.05).FEV1 % pred increased from(74.86 ± 4.34)to(80.02 ± 6.65)(P <0.05).FEV1 / FVC increased from baseline(71.75 ± 2.75)to(73.89 ± 13.19)(P < 0.05).During the treatment,2 patients(6 %)had adverse reactions,1 patient had redness and swelling at the injection site with skin itching,and 1 patient had mild fatigue and dizziness.Conclusions:The preliminary observation of omalizumab in the treatment of patients with moderate to severe allergic asthma has good clinical efficacy and few adverse reactions.